---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-037382"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T22:59:59.422385+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Trevi Therapeutics reports Q3 2022 net loss of $8.3M; cash at $126M

## Summary
- Net loss of $8.3M in Q3 2022 vs. $7.3M in Q3 2021; R&D expenses rose to $5.8M.
- Cash, cash equivalents, and investments totaled $126M as of Sept 30, 2022.
- Phase 2 CANAL trial for chronic cough in IPF met primary endpoint with 75.1% reduction in cough frequency (placebo-adjusted 52.5%, p<0.0001).
- Phase 2b/3 PRISM trial for prurigo nodularis open-label extension ongoing; end-of-phase 2 FDA meeting planned Q1 2023.

## SEC filing metadata
- accession: 0001564590-22-037382
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000156459022037382/0001564590-22-037382-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000156459022037382/trvi-8k_20221110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-037382
- JSON: https://secwatch.observer/filing/0001564590-22-037382.json
- Plain text: https://secwatch.observer/filing/0001564590-22-037382.txt

## Key facts
- Earnings Releases
  Trevi Therapeutics, Inc. reported quarter ended September 30, 2022 results: net income net loss of $8.3 million.
  - Period: quarter ended September 30, 2022
  - Net income: net loss of $8.3 million
  - Result: reported results
  source text: For the third quarter of 2022, the Company reported a net loss of $8.3 million, compared to a net loss of $7.3 million in the same period in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1563880/000156459022037382/0001564590-22-037382-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.